according to various estimates, the worldwide stockpiling market might be worth up to $4 billion, Dr de Lima says. “Since Tamiflu has been widely preferred to rival drug Relenza (zanamivir, Biota/GSK) by most governments based on its oral availability, Tamiflu sales due to stockpiling might potentially exceed $2 billion.”
http://www.pharmalive.com/News/index.cfm?a...2&categoryid=10